论文部分内容阅读
硫氧还蛋白(Trx)/硫氧还蛋白还原酶(TrxR)在许多人原发性肿瘤中和肿瘤病人的血样中是高表达的。其在促进肿瘤细胞增殖、抑制细胞凋亡、促进肿瘤耐药发生等事件中起到关键的推动作用,通过化疗药物抑制TrxR的活性已成为有效的癌症靶向治疗策略。国内外都开展了硫氧还蛋白系统抑制剂的探索工作,目前国际上进入临床研究的硫氧还蛋白系统的靶向药物只有三种,本文针对临床在研的这三种药物进行总结,以期开发出新型更高效的抗肿瘤新药。
Thioredoxin (Trx) / thioredoxin reductase (TrxR) is highly expressed in many human primary tumors and in blood samples from tumor patients. It plays a key role in promoting tumor cell proliferation, inhibiting apoptosis and promoting tumor drug resistance. Inhibiting the activity of TrxR by chemotherapy drugs has become an effective cancer targeted therapy strategy. At home and abroad have carried out exploration of thioredoxin system inhibitors, the current international access to clinical studies of the thioredoxin system, there are only three targeted drugs, clinical research in these three drugs are summarized, with a view to Developed a new type of more efficient anti-tumor drugs.